With regards to the origin of the tissue specimen used for mutational analysis, no statistically significant differences were identified in the percentages of EGFR mutations detected between samples obtained from primary tumours and those obtained from distant metastatic lesions, developed either through a lymphatic or hematogenous diffusion. This evidence concerns the gene EGFR and neoplasm.